Next Investors logo grey

Creso Pharma expands presence in Europe as it enters Portugal and Spain


Published 12-AUG-2020 10:36 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX: CPH | FRA: 1X8) has signed a commercial agreement with DHS Business Portugal to introduce the group’s products into the Portuguese and Spanish markets, effectively expanding the company’s presence in Europe.

DHS has been active in the healthcare markets since 1991 through its involvement in strategic consulting and commercialization operations in the US, Brazil, Latin America, Africa (Angola, Mozambique) and Portugal.

Creso established itself as a premium global standard developer of cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

In conjunction with DHS Business, Creso intends to initially focus its products on cannaDOL® 0.5% and 1% CBD topical gels to support the improvement of mobility.

These products target the sports population but also the demographic with diminished mobility due to Rheumatoid Arthritis and Arthrosis.

Further, Creso will also consider products sales of cannaQIX ®oral care addressing the needs of stress reduction and providing benefits for oral care management.

Creso and DHS Business are working on implementation plans, with a view to first products being sold in Spain and Portugal in the March quarter of 2021.


Aiming for more than 6000 points of sale

Commenting on this development, Creso Commercial Director Jorge Wernli said, “We are very much looking forward to entering the Portuguese and Spanish markets with our Creso topical and oral care products.

‘’These markets are very attractive, supporting us for further expansion into Latin America.’’

Creso and DHS Business aim to achieve a major coverage of sports shops and pharmacies offering over 2,000 points of sales in Portugal and over 4,000 points of sales in Spain.

The initial focus will be on the major cities of Lisbon, Sintra, Porto in Portugal whether population exceeds 4.5 million.

In Spain, the focus will be on Madrid, Barcelona, Valencia and Seville, which have a combined population of more than 6.2 million.

With the products, Creso and DHS Business aim to target the sports working and ageing population, representing approximately 50% of the total population or 3.8 million people.

Under the terms of the agreement, DHS Business will be paid an industry standard commission on sales of products.

No other fees were paid, or are payable, to any other party in relation to the agreement.

The agreement has an indefinite term, but may be terminated by 30 days’ notice by either party or forthwith for material breach.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.